Carcinoembryonic Antigen (Cea) Monitoring in the Management of Radiotherapeutic and Chemotherapeutic Patients

Vider, Manuel; Kashmin, R; Meeker, William R.; Moses, Bernard; Maruyama, Yosh

doi:10.2214/ajr.124.4.630

Cited by 18 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results showed that radiation therapy of localized colorectal cancer reliably reduced previously elevated circulating CEA titers. Even though radiotherapy did not always give prolonged control of tumor deposits, it significantly reduced all A 60-year-old man had localized perineal and urethral recurrence 6 years following Vider et al (1975) elevated CEA titers to near normal if tumor was confined to the irradiation port. It was suggested that significant decreases of elevated CEA titers with accumulating doses of irradiation indicated that the bulk of CEA producing recurrent or metastatic tumor was within the radiation portal and that if complete surgical resection of residual disease can be performed a favorable outcome may result.…”

Section: Patientmentioning

confidence: 98%

“…The patient remains clinically well 6 months later with minimal hepatomegaly and normal liver function tests; CEA has slowly begun to rise. Mulcare and Lo Gerfo (1972), Skarin et al (1974), andVider et al (1975) have A 63-year-old woman had abdominoperineal resection for Dukes C rectal carcinoma; Comment. Serial CEA assays correlate well with other clinical parameters in assessing disease progression or regression in patients treated with chemotherapy.…”

Section: Theoretical Basis For Clinical Application Of Serial Cea Assaysmentioning

confidence: 99%

See 1 more Smart Citation

Patterns of serial CEA assays and their clinical use in management of colorectal cancer

Sugarbaker¹,

Skarin²,

Zamcheck

1976

Journal of Surgical Oncology

View full text Add to dashboard Cite

Through persistent clinical research efforts, the CEA test has developed into a useful although complex disease monitor for colorectal cancer. Although improved or prolonged survival from its use has not been demonstrated, CEA monitoring may allow more knowledgeable patient management. Several reports indicate that postoperative serial CEA assays may identify patients with early recurrence, especially when assays are done frequently. Patients with elevated pretreatment CEA levels usually showed progressively rising titers before other objective evidence of recurrence was apparent. A progressively rising CEA titer correlated well with recurrent cancer, but a normal CEA could not be used as proof of its absence. Persistently elevated CEA titers post-treatment was caused either by persistent disease or by nontumor-related factors. The CEA assay was not a substitute for clinical follow-up but was an adjunct in the diagnosis of eary recurrence. Patients with elevated CEA levels caused by localized disease treated by radiation therapy demonstrated a marked fall in serial CEA levels if all CEA-producing tumor was localized within the radiation portal. The use of pretreatment CEA values plus the pattern of CEA reponse to irradiation may help in the selection of fulguration versus abdominoperineal resection as primary treatment for rectal cancer. Persistently low serial CEA titers after irradiation therapy correlated with disease control. The use of frequent serial CEA assays in patients treated with chemotherapy compared well with other parameters as a monitor of disease progression or regression. When used with other clinical parameters, serial CEA trends appeared to be a useful adjunct in assessing the effectiveness of chemotherapy. A fall in circulating CEA or the stabilization of a rising titer after starting chemotherapy usually indicated an effective regimen, whereas a rising CEA titer may signal may signal the need to initiate or to change chemotherapy.

show abstract

Section: Patientmentioning

confidence: 98%

Section: Theoretical Basis For Clinical Application Of Serial Cea Assaysmentioning

confidence: 99%

Patterns of serial CEA assays and their clinical use in management of colorectal cancer

Sugarbaker¹,

Skarin²,

Zamcheck

1976

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Assessment of serial carcinoembryonic antigen (CEA) assays in postoperative detection of recurrent colorectal cancer

Sugarbaker

Zamcheck

Moore

1976

Cancer

View full text Add to dashboard Cite

Monthly serial postoperative CEA ideterminations, three-monthly system review plus physical examination, and a battery of six-monthly laboratory and radio-logic tests were compared in order to evaluate each in detection of recurrent colorectal cancer. Twelve of the 33 patients studied prospectively developed recurrent disease. In this study CEA was found not to be a substitute for careful clinical follow-up, but if used in *a serial manner it was a useful adjunct for detection of early recurrent cancer, especially intra-hepatic and retroperitoneal disease recurring in patients with elevated pretreatment CEA levels. The other labokatory and radiologic tests employed were often useful to confirm progressing disease, but they did not reveal any first evidence of recurrent disease.

show abstract

Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer

Mayer

Garnick

Steele

et al. 1978

Cancer

View full text Add to dashboard Cite

A rising CEA level is accepted as a sensitive indicator of recurrent colorectal carcinoma. In order to assess its efficacy in monitoring responses to chemotherapy in disseminated disease, 47 patients with documented metastatic colorectal cancer were studied. All had pretreatment CEA determinations and 40/47 (85%) patients had CEA levels greater than 4.0 ng/ml. Patients with hepatic metastases had the highest CEA values and none were found to have levels less than 4.0 ng/ml. Thirty patients received chemotherapy and had serial CEA determinations. 4/30 (13.3%) demonstrated probable tumor regression, 7/30 (23.3%) had stable disease, while 19/30 (63.3%) showed disease progression. CEA titers declined in all four responders, but in only one instance did the level fall to below 4.0 ng/ml and provide evidence of a tumor response not appreciated clinically. The only cytotoxic drugs effecting tumor regressions were 5-FU and 5-FUDR. CEA levels usually rose as disease progressed, but once elevated, absolute values did not correlate directly with tumor burden. The further usefulness of CEA assays in monitoring disseminated colorectal cancer awaits the development of improved chemotherapeutic agents.

show abstract

Carcinoembryonic Antigen (Cea) Monitoring in the Management of Radiotherapeutic and Chemotherapeutic Patients

Cited by 18 publications

References 16 publications

Patterns of serial CEA assays and their clinical use in management of colorectal cancer

Patterns of serial CEA assays and their clinical use in management of colorectal cancer

Assessment of serial carcinoembryonic antigen (CEA) assays in postoperative detection of recurrent colorectal cancer

Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer

Contact Info

Product

Resources

About